Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FENC Stock Forecast 2026-2027
$10.60
Current Price
$368.21M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to FENC Price Targets
+69.8%
To High Target of $18.00
+50.9%
To Median Target of $16.00
+22.6%
To Low Target of $13.00
FENC Price Momentum
+2.8%
1 Week Change
+18.3%
1 Month Change
+18.8%
1 Year Change
+37.7%
Year-to-Date Change
-6.3%
From 52W High of $11.31
+87.6%
From 52W Low of $5.65
📊 TOP ANALYST CALLS
Did FENC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fennec Pharmaceuticals is one of their latest high-conviction picks.
Latest FENC Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, FENC has a bullish consensus with a median price target of $16.00 (ranging from $13.00 to $18.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $10.60, the median forecast implies a 50.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FENC Analyst Ratings
6
Buy
0
Hold
0
Sell
FENC Price Target Range
Low
$13.00
Average
$16.00
High
$18.00
Current: $10.60
Latest FENC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FENC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $16.00 |
| Apr 16, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Jan 9, 2026 | Piper Sandler | Overweight | Initiates | $N/A | |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 14, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 22, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 14, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 15, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 4, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 18, 2024 | Craig-Hallum | Buy | Maintains | $N/A | |
| Aug 4, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 21, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 6, 2023 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Apr 4, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Fennec Pharmaceuticals Inc. (FENC) Competitors
The following stocks are similar to Fennec Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fennec Pharmaceuticals Inc. (FENC) Financial Data
Fennec Pharmaceuticals Inc. has a market capitalization of $368.21M with a P/E ratio of 60.4x. The company generates $51.00M in trailing twelve-month revenue with a -16.4% profit margin.
Revenue growth is +72.6% quarter-over-quarter, while maintaining an operating margin of -0.8% and return on equity of -52.7%.
Valuation Metrics
Market Cap
$368.21M
Enterprise Value
$333.24M
P/E Ratio
60.4x
PEG Ratio
-0.5x
Price/Sales
7.6x
Growth & Margins
Revenue Growth (YoY)
+72.6%
Gross Margin
+96.2%
Operating Margin
-0.8%
Net Margin
-16.4%
EPS Growth
+72.6%
Financial Health
Cash/Price Ratio
+10.9%
Current Ratio
7.0x
Debt/Equity
0.0x
ROE
-52.7%
ROA
-5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fennec Pharmaceuticals Inc. (FENC) Business Model
About Fennec Pharmaceuticals Inc.
What They Do
Develops therapies for pediatric cancer treatment.
Business Model
Fennec Pharmaceuticals generates revenue by developing and commercializing innovative therapies, particularly focusing on reducing side effects of cancer treatments in pediatric patients. Their lead product, Pedmark, targets a specific niche by addressing ototoxicity in young cancer patients, thereby enhancing their quality of life during chemotherapy.
Additional Information
As a clinical-stage biopharmaceutical company, Fennec Pharmaceuticals is engaged in advancing its clinical trials and aims to meet significant unmet medical needs within the oncology sector. The company is strategically positioned in a growing market that emphasizes supportive care in cancer treatment, highlighting its potential for future growth and impact.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
35
CEO
Mr. Jeffrey S. Hackman
Country
United States
IPO Year
2017
Website
www.fennecpharma.comFennec Pharmaceuticals Inc. (FENC) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Jul 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
FENC stock has seen notable activity in the options market, signaling potential investor interest and volatility.
Why It Matters
FENC stock's options market activity signals potential volatility or shifts in investor sentiment, which can impact stock price and trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Fennec Pharmaceuticals granted 15,000 incentive stock options to a new non-executive employee on June 22, 2026, under its 2026 Equity Inducement Plan, as per Nasdaq rules.
Why It Matters
The grant of stock options to a new employee may signal company growth and attract talent, influencing investor confidence and potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Fennec Announces Results of Annual Meeting
1 month ago
Quick Summary
Fennec Pharmaceuticals announced the election of its director nominees at the Annual General Meeting held online on June 10, 2025.
Why It Matters
Board elections can signal strategic direction and governance quality, impacting investor confidence and stock performance for Fennec Pharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fennec Pharmaceuticals (NASDAQ: FENC) discussed its commercial strategy for PEDMARK, a sodium thiosulfate product aimed at preventing cisplatin-related hearing loss, at the H.C. Wainwright conference.
Why It Matters
Fennec Pharmaceuticals' strategy for PEDMARK highlights growth potential in a niche market, potentially impacting stock performance and investor interest in its future profitability.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Independent research on PEDMARK® (sodium thiosulfate injection) is increasing, potentially expanding its benefits to a broader and more diverse patient population.
Why It Matters
The expansion of research on PEDMARK® suggests potential market growth and increased adoption, which could positively impact the company’s revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fennec Pharmaceuticals granted 50,000 stock options to three new non-executive employees as part of its 2026 Equity Inducement Plan, effective May 18, 2026.
Why It Matters
The stock options granted to new employees signal Fennec Pharmaceuticals' commitment to attracting talent, potentially driving innovation and growth, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FENC Stock
What is Fennec Pharmaceuticals Inc.'s (FENC) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Fennec Pharmaceuticals Inc. (FENC) has a median price target of $16.00. The highest price target is $18.00 and the lowest is $13.00.
Is FENC stock a good investment in 2027?
According to current analyst ratings, FENC has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FENC stock?
Wall Street analysts predict FENC stock could reach $16.00 in the next 12 months. This represents a 50.9% increase from the current price of $10.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fennec Pharmaceuticals Inc.'s business model?
Fennec Pharmaceuticals generates revenue by developing and commercializing innovative therapies, particularly focusing on reducing side effects of cancer treatments in pediatric patients. Their lead product, Pedmark, targets a specific niche by addressing ototoxicity in young cancer patients, thereby enhancing their quality of life during chemotherapy.
What is the highest forecasted price for FENC Fennec Pharmaceuticals Inc.?
The highest price target for FENC is $18.00 from at , which represents a 69.8% increase from the current price of $10.60.
What is the lowest forecasted price for FENC Fennec Pharmaceuticals Inc.?
The lowest price target for FENC is $13.00 from at , which represents a 22.6% increase from the current price of $10.60.
What is the overall FENC consensus from analysts for Fennec Pharmaceuticals Inc.?
The overall analyst consensus for FENC is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are FENC stock price projections?
Stock price projections, including those for Fennec Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:14 PM UTC